{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:59:23Z","timestamp":1791824363037,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["humanpathol.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.humpath.2017.03.020","type":"journal-article","created":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T22:01:45Z","timestamp":1492120905000},"page":"30-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Cytokeratin 5\/6 expression, prognosis, and association with estrogen receptor \u03b1 in high-grade serous ovarian carcinoma"],"prefix":"10.1016","volume":"67","author":[{"given":"Eliane Tabea","family":"Taube","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Denkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina Alisa","family":"Kunze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Budczies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Dietel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Braicu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Darb-Esfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2017.03.020_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.humpath.2017.03.020_bb0015","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2017.03.020_bb0025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1006\/gyno.1998.4997","article-title":"\u201cRecurrence within 6 months of platinum therapy\u201d: an adequate definition of \u201cplatinum-refractory\u201d ovarian cancer?","volume":"69","author":"Markman","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2017.03.020_bb0030","first-page":"243","article-title":"Classification of human epithelia and their neoplasms using monoclonal antibodies to keratins: strategies, applications, and limitations","volume":"52","author":"Cooper","year":"1985","journal-title":"Lab Invest"},{"key":"10.1016\/j.humpath.2017.03.020_bb0035","first-page":"113","article-title":"Immunohistochemistry: update of applications and pitfalls","volume":"28 Pt 2","author":"Miettinen","year":"1993","journal-title":"Pathol Annu"},{"key":"10.1016\/j.humpath.2017.03.020_bb0040","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/modpathol.3880483","article-title":"Expression of cytokeratin 5\/6 in epithelial neoplasms: an immunohistochemical study of 509 cases","volume":"15","author":"Chu","year":"2002","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2017.03.020_bb0045","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","article-title":"The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory","volume":"34","author":"Kurman","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2017.03.020_bb0050","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1365-2559.2002.01352.x","article-title":"Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum","volume":"40","author":"Attanoos","year":"2002","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2017.03.020_bb0055","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/modpathol.3800534","article-title":"Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity","volume":"19","author":"Yaziji","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2017.03.020_bb0060","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/PAS.0b013e318033e7a8","article-title":"H-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary","volume":"31","author":"Comin","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2017.03.020_bb0065","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/01.pap.0000201832.15591.1d","article-title":"Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update","volume":"13","author":"Ord\u00f3\u00f1ez","year":"2006","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.humpath.2017.03.020_bb0070","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/modpathol.2008.108","article-title":"Immunophenotyping of serous carcinoma of the female genital tract","volume":"21","author":"Nofech-Mozes","year":"2008","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2017.03.020_bb0075","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1097\/IGC.0000000000000553","article-title":"Cytokeratin 5\u2013positive cells represent a therapy resistant subpopulation in epithelial ovarian cancer","volume":"25","author":"Corr","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.humpath.2017.03.020_bb0080","series-title":"WHO classification of tumours of the breast","first-page":"30","year":"2012"},{"key":"10.1016\/j.humpath.2017.03.020_bb0085","doi-asserted-by":"crossref","first-page":"37","DOI":"10.5858\/arpa.2012-0439-RA","article-title":"Basal-like breast cancer: update on clinicopathologic, immunohistochemical, and molecular features","volume":"138","author":"Leidy","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2017.03.020_bb0090","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ygyno.2007.12.003","article-title":"Hormone replacement therapy and ovarian cancer risk: a meta-analysis","volume":"108","author":"Zhou","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2017.03.020_bb0095","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S0140-6736(07)60534-0","article-title":"Ovarian cancer and hormone replacement therapy in the Million Women Study","volume":"369","author":"Beral","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.humpath.2017.03.020_bb0100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1476-4598-11-69","article-title":"Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer\u2014a study of the OVCAD consortium","volume":"11","author":"Aust","year":"2012","journal-title":"Mol Cancer"},{"key":"10.1016\/j.humpath.2017.03.020_bb0105","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1677\/ERC-08-0338","article-title":"Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue","volume":"16","author":"Darb-Esfahani","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.humpath.2017.03.020_bb0110","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","article-title":"Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humpath.2017.03.020_bb0115","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11912-013-0343-3","article-title":"Hormonal treatment in recurrent and metastatic gynaecological cancers: a review of the current literature","volume":"15","author":"Sommeijer","year":"2013","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.humpath.2017.03.020_bb0120","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2559.2010.03544.x","article-title":"Expression of classical NF-kappaB pathway effectors in human ovarian carcinoma","volume":"56","author":"Darb-Esfahani","year":"2010","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2017.03.020_bb0125","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2307\/2531021","article-title":"Sample-size formula for the proportional-hazards regression model","volume":"39","author":"Schoenfeld","year":"1983","journal-title":"Biometrics"},{"key":"10.1016\/j.humpath.2017.03.020_bb0130","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s00428-003-0859-2","article-title":"Distribution of p63, cytokeratins 5\/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray","volume":"443","author":"Reis-Filho","year":"2003","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2017.03.020_bb0135","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/modpathol.3800259","article-title":"Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma","volume":"18","author":"Chu","year":"2005","journal-title":"Mod Pathol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817717301053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817717301053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T14:28:04Z","timestamp":1535898484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817717301053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":25,"alternative-id":["S0046817717301053"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2017.03.020","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokeratin 5\/6 expression, prognosis, and association with estrogen receptor \u03b1 in high-grade serous ovarian carcinoma","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2017.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}